
oct pm et
summari lead develop manufactur provid analyt instrument
complex servic life scienc drug discoveri industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
broad product line geograph coverag span
life scienc health care industri market
singl custom account total
revenu reduc risk view balanc
intens competit industri compani oper
howev cut edg technolog requir
remain relev present technolog risk
obsolesc fact consist
report strong
patheon acquisit increas
earn organ growth acceler
across segment report top-lin
growth yoy aid
organ growth yoy materi uptick
averag
sale china total also
remain strong growth yoy
overal growth acceler come
peer lose sale momentum indic
us breadth product line
help gain market share particularli
oper also improv ebita margin
bp yoy contain sg major
factor cost grew yoy vs
revenu expect
improv margin
mark year patheon acquisit
typic achiev materi cost
synergi previous multi-billion
dollar acquisit
also paid debt last
year bring debt/ebita one
lowest level sinc expect
focu capit alloc effort
like dual strategi invest heavili
intern innov organ growth
pursu leverag broader product
line invest new technolog
unriv estim combin
 capital-expenditure spend approxim
 front execut reward
formula use debt acquir improv
margin pay debt repeat
sinc done worth
acquisit steadili increas ebita
margin estim
improv oper respons use
debt help increas roe
bp period expect
accret resum next year
patheon debt paid risk
view includ slump end market
particularli pharma cut lack
target ep estim
peer-averag expect continu
gain market share conveni
broad servic offer custom also
comfort price-to-earnings premium free
cash flow yield histor averag
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview thermo fisher scientif lead provid life scienc tool
servic broad array end market includ pharma/biotech compani academ govern
institut diagnost health care compani industri appli scienc compani
product servic includ laboratori analyt instrument biochem reagent laboratori
medic consum softwar servic research analysi discoveri diagnosi
product instrument scientif innov around world divers field drug discoveri
environment regulatori complianc food safeti think market repres combin
billion billion annual marketplac think largest compani within marketplac
broadest product offer geograph coverag
life scienc solut sale compris primarili acquir
busi see corpor strategi focus genet sequenc instrument servic
analyt sale compris primarili legaci thermo electron busi
merger focus primarili develop manufactur analyt system
instrument compon segment also provid softwar solut monitor collect
specialti diagnost sale focus diagnost instrument assay use
determin content qualiti molecul
laboratori product servic sale compris primarili legaci fisher scientif
busi focus lab equip consum well biopharma outsourc servic
corpor strategi think strength lie extens product offer geograph
coverag one-stop shop strategi allow scientist research health care profession
order divers product need time cost-effect manner one sourc
continu expand product portfolio extens intern develop
extern growth via acquisit estim combin capital-expenditure roughli
line next three largest competitor combin also proven extrem effect
streamlin oper acquir firm period saw execut worth
acquisit steadili increas ebita margin period recent
notabl acquisit includ august acquisit patheon billion septemb
acquisit fei compani billion march acquisit affymetrix billion
februari acquisit billion
lead provid life scienc tool servic includ next gener genet
sequenc acquisit greatli expand life scienc segment revenu
enabl quickli gain sizabl market share fast-grow genet sequenc
market although expect remain clear leader life scienc highest oper
margin among segment expect continu materi contributor organ growth
patheon ebita margin stand-alon busi lower compani averag
appear execut cost synergi overal ebita margin maintain
august acquisit also see strong revenu growth opportun patheon
clinic trial servic bioproduct technolog expect improv margin scale grow
competit landscap life scienc tool servic scientif product servic
marketplac highli fragment highli competit think may competit advantag
peer due purchas power oper leverag broad product offer
water corp among privat held firm primari competitor
financi trend sale increas billion billion repres
five-year compound annual growth rate compound-annual-growth-rate prolif acquir acquisit
aid sale growth howev compani also streamlin variou oper divest
busi well ebita margin increas adjust ep
rose repres compound-annual-growth-rate
board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grown rapidli last three
year materi increas fund
academ govern lab turn
drive sale growth lst compani
view sub-industri deriv materi
portion revenu lab fy
nih budget grew
fy
think budget increas aid
lst sub-industri sale growth
estim
expect increas public fund support
robust demand sub-industri
product come year well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri year end june
estim spend
increas year-over-year
spend biotech
compar estim annual increas
pharma respect
year end june think
acceler spend translat
solid sale growth life scienc
tool servic sub-industri
depart research tool product
well contract research servic
clinic drug trial see type growth
continu year ahead
beyond biopharmaceut custom
believ health care research type
prolifer around world particularli
china emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani view china
particular use five largest compani
sub-industri proxi estim
sub-industri sale chines
custom grown
versu prior-year period compar
total revenu growth
think china certain emerg market
nation need continu rapidli increas
health care expenditur parallel
grow middl class turn
continu support strong sale growth
see happen despit threat
import/export tariff believ
limit large-scal supplier option
state-of-the-art lst product outsid
compani one notabl except
 life scienc tool
servic rose vs rise
 composit index year date
octob life
scienc tool servic index risen
vs rise
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra add thermo fisher scientif high-qual capit
appreci port largest life scienc compani
unmatch product offer along signific geograph presenc
view compani oper four busi segment analyt instrument
life scienc solut specialti diagnost laboratori product also
maintain lead market share mani market grown
well-balanc capit deploy strategi includ acquisit
supplement organ growth well stock buyback dividend replac
ci high-qual capit appreci portfolio /jeffrey loo cfa
fisher scientif rais target
slightli peer ep estim
set ep vs ahead
estim sale rose organ growth saw broad-bas product
geograph growth biopharma market grew govt/academ
diagnost rose high-singl digit industri rose mid-singl
digit expect oper margin declin lower pantheon
margin see leverag synergist benefit aid margin
et cfra reiter buy opinion share
thermo fisher scientif announc
deal enabl sell ion ampliseq technolog research
util next-gener sequenc platform sell
product name ampliseq continu
sell custom share rose significantli follow
announc deal two largest firm genet
sequenc space rais possibl partnership rais
target peer ep estim
analyst research note compani news
scientif inc keep target
slightli above-p averag ep estim expect
above-averag growth initi ep estim ep
vs beat estim report strong quarter
view top-lin growth yoy fuel patheon
acquisit last year acceler organ growth segment
especi impress acceler organ sale growth life
scienc yoy believ indic
grow market share rapidli grow field especi import
given life scienc largest segment profit total
also improv oper margin bp yoy led success sg
contain effort expect margin improv next year
strong track record streamlin second year larg
acquisit case patheon next year /colin scarola
buy strong buy keep target
slightli below-p averag ep estim see rapid
organ acquisit growth recent year becom difficult
sustain due greatli increas scale follow patheon
acquisit august rais ep estim
opinion chang relat valuat share price increas
year-to-d push forward price-to-earnings multipl well beyond
averag respect expect growth remain strong particularli
china sale grow becom cautiou
valuat given larg scale like make meaning growth harder
achiev futur year remain support dual-strategi
invest heavili intern innov pursu acquisit track
record increas seri three major acquisit
past five year impress /colin scarola
et cfra reiter strong buy opinion share thermo
fisher scientif rais target
slightli peer forward ep estim
discount growth acquisit ep vs
ahead view rais ep estim
ep estim sale contribut acquisit
rose ahead growth forecast organ growth robust
growth broad-bas across end market geographi life scienc
analyt instrument specialti diagnost lab
product includ patheon acquisit sale china rose
see posit across divers end market geographi key
strength attract client across globe main supplier
instrument consum launch new product includ
q-exact uhmr protein research immunoassay analyz
see contribut growth /jeffrey loo cfa
fisher scientif keep target price
slightli peer ep estim
discount growth acquisit ep vs
ahead estim sale rose organ growth
contribut acquisit ahead sale growth forecast
pharmaceut biotech end market remain robust see
compani gain market share expand valu proposit offer
recent addit pantheon encourag robust
organ growth rate anticip among highest life
scienc space quarter see sale growth driven new product innov
signific grow market share emerg market
particularli china howev anticip oper margin declin
due integr pantheon lower margin howev
look better margin /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
